Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) have demonstrated efficacy in reducing cardiovascular events and potentially improving kidney function in diabetic patients. Here, using the TriNetX platform, the authors show that SGLT-2 inhibitors reduce all-cause mortality and major adverse cardiac and kidney events in diabetic kidney transplant recipients.
- Jia-Yuh Sheu
- Li-Yang Chang
- Vin-Cent Wu
